热疗联合化疗治疗晚期非小细胞肺癌临床观察

Clinical observation of hyperthermia combined with chemotherapy in the treatment of advanced non-small cell lung cancer

目的:观察全身化疗加热疗及单纯全身化疗治疗晚期非小细胞肺癌的临床疗效,毒副反应及临床受益率。方法:60例晚期非小细胞肺癌患者入组,其中热化疗组(A组)32例,单纯化疗组(B组)28例,均采用NP(长春瑞滨+顺铂)或GP(吉西他滨+顺铂)方案化疗2个周期。热化疗组使用(13.56±0.2)MHz高频热疗机同步进行局部热疗,每周2次,共10次。结果:热化疗组有效率21.9%,单纯化疗组14.3%,两组有效率差异无统计学意义(P>0.05);热化疗组临床受益率为68.8%,而单纯化疗组为35.7%,两组临床受益率差异有统计学意义(P<0.05)。两组患者治疗前后KPS评分的变化有统计学意义,两组毒副作用无明显差异,中位生存期有显著差异(11.2vs16.3个月)。结论:临床观察显示热、化疗联合治疗晚期非小细胞肺癌具有良好的耐受性和较好的近期疗效。

Objective：To observe the clinical efficacy,side effects, and clinical benefit response induced by systemic chemotherapy plus hyperthermia or systemic chemotherapy in the treatment of patients with advanced non-small cell lung cancer （NSCLC）. Methods： A total of 60 patients with advanced NSCLC were recruited with 32 cases in systemic chemotherapy plus hyperthermia group （Group A） and 28 cases in systemic chemotherapy group （Group B）. The patients in the two groups received NP （vinorelbine＋cisplatin） or GP （gemcitabine＋cisplatin） regimens for 2 cycles. In addition, the patients in group A received local hyperthermia therapy at （13.56±0.2） MHz twice a week for 5 weeks. Results：The response rate in group A was 21.9% and 14.3% in group B. The difference was not significant （P〉0.05）. The clinical benefit response in group A was 68.8% and 35.7% in group B. There was significant difference between the two groups （P〈0.05）, The difference was significant in the change of KPS score before and after treatment between the two groups. The toxic and side effects of the two groups had no significant difference but the difference in median survival time was significant （11. 2 vs 16. 3 months）, Conclusion： Hyperthermia combined with chemotherapy has better tolerance and short-term efficacy in the treatment of patients with advanced NSCLC.